WO2001051664A3 - Procede de detection et de caracterisation d'un neoplasme - Google Patents

Procede de detection et de caracterisation d'un neoplasme Download PDF

Info

Publication number
WO2001051664A3
WO2001051664A3 PCT/US2001/001081 US0101081W WO0151664A3 WO 2001051664 A3 WO2001051664 A3 WO 2001051664A3 US 0101081 W US0101081 W US 0101081W WO 0151664 A3 WO0151664 A3 WO 0151664A3
Authority
WO
WIPO (PCT)
Prior art keywords
detecting
neoplasm
characterizing
disclosed
methods
Prior art date
Application number
PCT/US2001/001081
Other languages
English (en)
Other versions
WO2001051664A2 (fr
Inventor
Katherine J Martin
Arthur Pardee
Ruth Di Sager
Original Assignee
Dana Farber Cancer Inst Inc
Katherine J Martin
Arthur Pardee
Pardee Arthur Hm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Katherine J Martin, Arthur Pardee, Pardee Arthur Hm filed Critical Dana Farber Cancer Inst Inc
Publication of WO2001051664A2 publication Critical patent/WO2001051664A2/fr
Publication of WO2001051664A3 publication Critical patent/WO2001051664A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)

Abstract

L'invention concerne des procédés de détection de néoplasmes, par exemple des carcinomes mammaires, à l'aide de gènes exprimés de manière différentielle. Elle concerne également des procédés permettant d'identifier des agents de traitement de néoplasmes.
PCT/US2001/001081 2000-01-12 2001-01-12 Procede de detection et de caracterisation d'un neoplasme WO2001051664A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17566900P 2000-01-12 2000-01-12
US60/175,669 2000-01-12

Publications (2)

Publication Number Publication Date
WO2001051664A2 WO2001051664A2 (fr) 2001-07-19
WO2001051664A3 true WO2001051664A3 (fr) 2002-09-06

Family

ID=22641159

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/001081 WO2001051664A2 (fr) 2000-01-12 2001-01-12 Procede de detection et de caracterisation d'un neoplasme

Country Status (1)

Country Link
WO (1) WO2001051664A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001067103A1 (fr) 2000-03-06 2001-09-13 Bioseek, Inc. Criblage d'homologie de fonctions
US6763307B2 (en) * 2000-03-06 2004-07-13 Bioseek, Inc. Patient classification
WO2002099421A2 (fr) * 2001-05-18 2002-12-12 Thomas Jefferson University Jeux ordonnes de microechantillons specifiques destines a la detection du cancer du sein
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
JP4943074B2 (ja) * 2006-07-03 2012-05-30 シスメックス株式会社 がん転移の判定方法及び装置
GB201000688D0 (en) * 2010-01-15 2010-03-03 Diagenic Asa Product and method
US20150299806A1 (en) * 2012-11-20 2015-10-22 University Of Tromsoe Gene expression profile in diagnostics

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029430A1 (fr) * 1995-03-17 1996-09-26 John Wayne Cancer Institute Depistage du melanome ou des metastases dans le sein a l'aide d'un titrage par marqueurs multiples
WO1999001581A1 (fr) * 1997-07-02 1999-01-14 Genzyme Corporation Expression genetique influencee par p53
WO1999044062A1 (fr) * 1998-02-25 1999-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services Arrangements cellulaires permettant une definition de profil moleculaire rapide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029430A1 (fr) * 1995-03-17 1996-09-26 John Wayne Cancer Institute Depistage du melanome ou des metastases dans le sein a l'aide d'un titrage par marqueurs multiples
WO1999001581A1 (fr) * 1997-07-02 1999-01-14 Genzyme Corporation Expression genetique influencee par p53
WO1999044062A1 (fr) * 1998-02-25 1999-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services Arrangements cellulaires permettant une definition de profil moleculaire rapide

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
BREAST CANCER RESEARCH AND TREATMENT, vol. 37, no. 2, 1996, pages 179 - 188, ISSN: 0167-6806 *
CANCER RESEARCH, vol. 60, no. 8, April 2000 (2000-04-01), pages 2232 - 2238, ISSN: 0008-5472 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1992, MATSUMURA YASUHIRO ET AL: "Significance of CD44 gene products for cancer diagnosis and disease evaluation.", XP002188524, Database accession no. PREV199395040761 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, BUESO-RAMOS CARLOS E ET AL: "Abnormal expression of MDM-2 in breast carcinomas.", XP002188523, Database accession no. PREV199698698113 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 2000 (2000-04-01), MARTIN KATHERINE J ET AL: "Linking gene expression patterns to therapeutic groups in breast cancer.", XP002188525, Database accession no. PREV200000214990 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; DRABEROVA E ET AL: "Expression of class III beta-tubulin in normal and neoplastic human tissues.", XP002188292, retrieved from STN Database accession no. 1998200544 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; RANGANATHAN S ET AL: "Immunohistochemical analysis of beta-tubulin isotypes in human prostate carcinoma and benign prostatic hypertrophy.", XP002188293, retrieved from STN Database accession no. 97265698 *
HISTOCHEMISTRY AND CELL BIOLOGY, (1998 MAR) 109 (3) 231-9. *
JIANG MING ET AL: "p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis.", INTERNATIONAL JOURNAL OF CANCER, vol. 74, no. 5, 21 October 1997 (1997-10-21), pages 529 - 534, XP002188291, ISSN: 0020-7136 *
LANCET (NORTH AMERICAN EDITION), vol. 340, no. 8827, 1992, pages 1053 - 1058, ISSN: 0099-5355 *
MARTIN K J ET AL: "IDENTIFICATION AND VERIFICATION OF DIFFERENTIAL DISPLAY CDNAS USINGGENE-SPECIFIC PRIMERS AND HYBRIDIZATION ARRAYS", BIOTECHNIQUES, EATON PUBLISHING, NATICK, US, vol. 24, no. 6, 1 June 1998 (1998-06-01), pages 1018 - 1024,1026, XP000780498, ISSN: 0736-6205 *
MARTIN KATHERINE J ET AL: "High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 5, 27 February 2001 (2001-02-27), February 27, 2001, pages 2646 - 2651, XP002188522, ISSN: 0027-8424 *
MARTIN, K. J. (1) ET AL: "A hybridization array assay using differential display-identified markers for early detection and staging of breast cancer.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1999) VOL. 40, PP. 319. MEETING INFO.: 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH PHILADELPHIA, PENNSYLVANIA, USA APRIL 10-14, 1999 AMERICAN, XP001026342 *
PROSTATE, (1997 MAR 1) 30 (4) 263-8. *
SGROI D C ET AL: "IN VIVO GENE EXPRESSION PROFILE ANALYSIS OF HUMAN BREAST CANCER PROGRESSION", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 22, 15 November 1999 (1999-11-15), pages 5656 - 5661, XP000994514, ISSN: 0008-5472 *
TANAKA TAKEO ET AL: "Prognostic discrimination among neuroblastomas according to Ha-ras/trk A gene expression: A comparison of the profiles of neuroblastomas detected clinically and those detected through mass screening.", CANCER, vol. 83, no. 8, 15 October 1998 (1998-10-15), pages 1626 - 1633, XP002188290, ISSN: 0008-543X *
YOUNGS SARA J ET AL: "Chemokines induce migrational responses in human breast carcinoma cell lines.", INTERNATIONAL JOURNAL OF CANCER, vol. 71, no. 2, 1997, pages 257 - 266, XP002166394, ISSN: 0020-7136 *

Also Published As

Publication number Publication date
WO2001051664A2 (fr) 2001-07-19

Similar Documents

Publication Publication Date Title
WO2001070979A3 (fr) Nouveaux genes, compositions, trousses et methodes d'identification, de verification, de prevention et de traitement du cancer des ovaires
EG23200A (en) Method for treating multiple wellbore intervals.
AU2001293257A1 (en) Method for amortizing authentication overhead
AU5439899A (en) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as cetp inhibitors
AU2001227966A1 (en) Methods for treating tumors
AU2001283139A1 (en) Method of treating estrogen receptor positive carcinoma
AP2000002011A0 (en) Method for making 4-carboxyamino-2-substituted-1,2,3,4- tetrahydroquinoline.
IL173393A0 (en) 4-carboxyamino-2- substituted-1,2,3,4- tetrahydroquinolines as cetp inhibitors
ZA997287B (en) An improved promotional financial transaction machine method.
HK1045888A1 (zh) 信息處理方法、任務間通信方法及其計算機可執行程序
MXPA02003718A (es) Metodo de multiaspas para hidromejorar tejidos.
SG101967A1 (en) Authentication system, authentication method, authentication apparatus, and authentication method therefor
AU2002312445A1 (en) Methods of detecting, diagnosing and treating cancer and identifying neoplastic progression
AU2003253440A1 (en) Method of diagnosing ovarian endometriosis
GB2363810B (en) Processes for treating subterranean formations
AU3724100A (en) An efficient method for subsurface treatments, including squeeze treatments
WO2001051664A3 (fr) Procede de detection et de caracterisation d'un neoplasme
EP1358225B8 (fr) Procede pour le traitement de polymerisats par emulsion
WO2002058533A3 (fr) Procede pour determiner la fonction de cibles et identifier des tetes de serie de medicaments
ITBO990293A0 (it) Metodo di controllo di banconote .
AU5867901A (en) Method for detecting tumors
WO2004031774A3 (fr) Methode de traitement ou de prevention de metastases de cancers colorectaux
AU2001272578A1 (en) Precalendering method, finishing method and apparatus for implementing the methods
AU1700700A (en) Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis
WO2001085152A3 (fr) R-eliprodil applique au traitement du glaucome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP